MDXH

MDxHealth S.A. (MDXH) Economic Moat Analysis (2026)

Invetso Score: 2.4/10 — Weak · Last Updated: 2026-09-01

Overall Score

Scale Market Position

Revenue base remains small at a $36.5M market cap and $102.5M enterprise value, limiting scale advantages.

TTM revenue per share is only 1.62, suggesting a modest operating footprint.

Profitability Returns

Gross margin is solid at 57.7%, but operating margin (-16.6%) and net margin (-32.2%) remain deeply negative.

Returns are poor, with ROIC at -12.7% and ROA at -17.7%, indicating no durable economic moat in current operations.

Cash Generation Reinvestment

Free cash flow remains negative on a yield basis, with FCF yield at -4.5% and operating cash flow yield at -2.5%.

Capex is light relative to revenue, but weak cash conversion and negative operating cash flow limit reinvestment flexibility.

Balance Sheet Resilience

Liquidity is only modest, with a current ratio of 1.08 and quick ratio of 0.94.

Leverage and coverage remain strained, with negative interest coverage and debt-to-capital above 1.0, reducing financial resilience.

Moat Durability Intangibles

High SG&A at 40.7% of revenue suggests the business still needs heavy spending to sustain its position.

Intangibles make up 53.0% of total assets, but there is no clear evidence yet of pricing power or network effects translating into durable returns.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MDxHealth S.A.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →